🔴 SAB Biotherapeutics is trading 7.6% down in pre-market with no clear company-specific catalyst identified

SAB Biotherapeutics is trading at $2.66, down 7.64% versus the October 7 close, with no clear company-specific catalyst identified for the October 8 pre-market decline.

• The company’s latest listed release, dated October 1, announced presentations at an upcoming research congress and did not report a new overnight event.
• Broader markets are under pressure, but supplied index moves are mixed and do not establish the cause of the decline. No pre-market volume information was available.